Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 30 of 95, showing 5 Applications out of 474 total, starting on record 146, ending on 150

# Protocol No Study Title Investigator(s) & Site(s)

146.

ECCT/17/05/04   Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost
    A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WALTER REED KERICHO
 
View

147.

ECCT/18/07/07   A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc
    A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. GRACE KIRINGA KAGUTHI
Site(s) in Kenya
1. Center for Respiratory Diseases Research (Siaya county)
2. KEMRI (Kisumu county)
 
View

148.

ECCT/19/01/01   A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc
    A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria   
Principal Investigator(s)
1. Bernhards Ogutu Ragama
Site(s) in Kenya
1. Ahero County hospital (Kisumu county)
2. Siaya County Hospital (Siaya county)
 
View

149.

ECCT/16/11/05   RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo
    A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo.   
Principal Investigator(s)
1. Fredrick Kipyego Sawe
Site(s) in Kenya
1. KEMRI/WRP Kericho (Kericho county)
2. KEMRI/WRP Kombewa, Kisumu (Kisumu county)
 
View

150.

ECCT/16/11/04   RV456
    A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo   
Principal Investigator(s)
1. JANET OYIEKO
Site(s) in Kenya
KOMBEWA CLINICAL RESEARCH CENTRE
 
View